Aliphatic amino-substituted demethoxylated hypocrellins and their synthesis
View Patent ↗The invention involves a methods and compositions for use in photodynamic therapy. Novel perylenequinone derivatives, conjugates comprising perylenequinone derivatives and a binding agent, and methods of treatment using these compositions are disclosed. The present invention relates to the field of photosensitizers possessing photodynamic activities. They possess high photodynamic activities and low dark toxicities, which makes them as more potent photodynamic agents than HPD against cancer and AIDS virus.
1. A composition comprising at least one of an amino-substituted demethoxylated hypocrellin derivative according to the following structures:
wherein R 1 , R 2 , R 3 , R 4 are OCH 3 , NHCH 2 Ar, NHCH(CH 2 ) x , or NHCH(CH 2 ) n Ar, with the proviso that at least one of R 1 , R 2 , R 3 and R 4 is NHCH 2 Ar, NHCH(CH 2 ) x or NHCH(CH 2 ) n Ar, wherein Ar is a phenyl, naphthyl, pyridyl group, polycyclic aromatic group, or a heterocyclic moiety, and wherein —CH(CH 2 ) x is an alicyclic group, x=3, 4, 5, or 6 and n is 0–12.
2. The composition of claim 1 wherein R 1 and R 2 , are OCH 3 , and R 3 and R 4 are OCH 3 , NHCH 2 Ar, or NHCH 2 (CH 2 ) n Ar, with the proviso that at least one of R 3 and R 4 is NHCH 2 Ar, or NHCH 2 (CH 2 ) n Ar.
3. The composition of claim 1 , wherein R 1 , R 2 , R 3 , and R 4 are OCH 3 , NHCH 2 Ar, or NHCH(CH 2 ) x with the proviso that at least one of R 1 , R 2 , R 3 , or R 4 is NHCH 2 Ar or NHCH(CH 2 ) x , wherein Ar is a phenyl or pyridyl group.
4. A method of producing a demethoxylated hypocrellin derivative of claim 1 , comprising:
dissolving a hypocrellin in a solvent containing an aliphatic amine, and stirring the resulting solution;
removing the solvent, to produce a residue;
washing the residue; and
separating the residue.
5. The method of claim 4 wherein separating the residue comprises using thin-layer chromatography to separate the residue.
6. A method according to claim 4 , wherein the hypocrellin is hypocrellin A or hypocrellin B.
7. A method according to claim 4 , wherein the aliphatic amine is cyclopentylamine, cyclohexylamine, benzylamine, 3-pyridylmethylamine or 4-pyridylmethylamine.
8. A method according to claim 4 , wherein the aliphatic amine is cyclobutylamine, histamine, 2-thiophenemethylamine, 2-pyrrolmethylamine, or tryptamine.
9. The method according to claim 4 , wherein the solvent is benzene, pyridine, cyclohexane or 1,4-dioxane.
10. The method according to claim 4 , wherein the solvent is chlorobenzene, toluene, hexanes, petroleum ether, tetrahydrofuran, or N,N-dimethylformamide.
11. A method of treatment comprising administering a demethoxylated hypocrellin derivative, and activating the demethoxylated hypocrellin derivative by exposing the demethoxylated hypocrellin derivative to light of a predetermined wavelength, wherein the hypocrellin derivative is an amino-substituted demethoxylated hypocrellin derivative comprising at least one of the following structures:
wherein R 1 , R 2 , R 3 , R 4 are OCH 3 , NHCH 2 Ar, NHCH(CH 2 ) x , or NHCH(CH 2 ) n Ar, with the proviso that at least one of R 1 , R 2 , R 3 , or R 4 is NHCH 2 Ar, NHCH(CH 2 ) x , or NHCH(CH 2 ) n Ar and wherein —CH(CH 2 ) x is an alicyclic group and x=3, 4, 5, or 6, and wherein Ar is a phenyl, pyridyl group, naphthyl, polycyclic aromatic, or a heterocyclic moiety, and n is 0–12.
12. The method of claim 11 , wherein R 1 , R 2 , R 3 , R 4 are OCH 3 or NHCH 2 (CH 2 )Ar, and Ar is a phenyl, naphthyl, polycyclic aromatic, or a heterocyclic moiety, and n is 0–12.
13. The method of claim 11 , wherein R 1 , R 2 , R 3 , and R 4 are OCH 3 , NHCH 2 Ar, or NHCH(C 2 ) x , wherein Ar is a phenyl or pyridyl group, and wherein —CH(CH 2 ) x is an alicyclic group, and n is 3, 4, 5, or 6.